Related Experiment Video
Updated: Dec 23, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis
JinSong Geng1, HaiNi Bao1, YaLan Chen1
1Evidence-based Medicine Center, Medical School of Nantong University , Jiangsu, China.
Insights
Nucleos(t)ide analogues effectively treat chronic hepatitis B (CHB) by improving viral DNA levels and seroconversion markers. These treatments are safe, with no increased serious adverse events compared to placebo.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis B (CHB) is a significant global health concern, leading to severe liver disease.
- Hepatitis B virus (HBV) infection necessitates effective therapeutic strategies to prevent cirrhosis and liver cancer.
Purpose of the Study:
- To evaluate the efficacy and safety of nucleos(t)ide analogues for treating CHB.
- To compare the effectiveness of different nucleos(t)ide analogues in managing CHB.
Main Methods:
- Systematic literature search and meta-analyses, including direct comparison and network meta-analysis (NMA).
- Inclusion of 36 randomized controlled trials (RCTs) comparing nucleos(t)ide analogues against placebo or each other.
Main Results:
- Nucleos(t)ide analogues demonstrated efficacy in HBeAg seroconversion, HBeAg loss, and achieving undetectable HBV DNA compared to placebo.
- Tenofovir showed the best performance for HBeAg loss and undetectable HBV DNA, while entecavir was potent for ALT normalization.
- No significant increase in serious adverse events was observed with nucleos(t)ide analogues versus placebo.
Conclusions:
- Nucleos(t)ide analogues are effective treatments for CHB, improving key virological and biochemical markers.
- Further high-quality, long-term RCTs are recommended to solidify findings and guide clinical practice.
Objectives:
Chronic hepatitis B (CHB) is a major global health problem caused by hepatitis B virus (HBV) infection, and can put patients at high risk of death from cirrhosis and liver cancer. However, CHB can be treated with nucleos(t)ide analogues. We aimed to evaluate the effectiveness and safety of nucleos(t)ide analogues for the treatment of CHB patients.
Methods:
A systematic literature search was performed. Direct comparison meta-analyses and network meta-analysis (NMA) were carried out.
Results:
Thirty-six randomized controlled trials (RCTs) met inclusion criteria. Compared with placebo, the nucleos(t)ide analogues were all effective in HBeAg seroconversion, HBeAg loss, and achieving undetectable HBV DNA. Telbivudine was associated with higher HBeAg seroconversion compared with entecavir. For HBeAg loss rate and proportion of achieving undetectable HBV DNA, tenofovir ranked as the best. Entecavir might be the most potent in the normalization of alanine aminotransferase (ALT). The nucleos(t)ide analogues did not have higher serious adverse events rate as compared with placebo.
Conclusion:
The nucleos(t)ide analogues are all effective for HBeAg seroconversion, HBeAg loss, undetectable HBV DNA, and most are effective for ALT normalization in adults with CHB. RCTs of multi-center, low risk of bias, and long-term follow-up are still needed.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Retrovirus Life Cycles
Subviral Agents
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Viruses with RNA Genomes